The control and eradication of malaria demands a multifaceted approach. At present we have a range of good tools, including insecticide spraying and long-lasting insecticide-treated bed nets help to prevent the transmission of the infection via the mosquito vector. But no preventative strategy is 100% effective – there will always be cases that slip through the net. The current WHO-recommended first-line treatment for the majority of malaria cases is artemisinin-based combination therapy (ACT). These medicines, in addition to diagnostics, are available to treat and in some cases prevent malaria.
Guidelines for the treatment of malaria:
Treatment of malaria depends on the species of malaria, as well as on the severity of the disease. The World Health Organization's Guidelines for the treatment of malaria provides recommendations on topics such as:
- Treatment of uncomplicated p. falciparum malaria
- Treatment of uncomplicated malaria caused by p. vivax
- Treatment of severe malaria
- Mass drug administration
- .... and more
Developing effective antimalarials to save lives:
MMV’s portfolio focuses on delivering efficacious medicines that are affordable, accessible and appropriate for use in malaria endemic areas. Specifically, the goal is to develop products that will provide: efficacy against drug-resistant strains of Plasmodium falciparum, potential for intermittent treatments (infants and pregnancy), safety in small children (less than 6 months old), safety in pregnancy, efficacy against Plasmodium vivax (including radical cure), efficacy against severe malaria, and transmission-blocking treatment.
Facilitating delivery of new, effective and affordable antimalarial drugs:
MMV’s Access and Product Management (APM) team ensures that new innovative antimalarials emerging from our pipeline reach those in need and save lives.